Non-cytotoxic systemic treatment in malignant peripheral nerve sheath tumors (MPNST): A systematic review from bench to bedside.

[1]  D. Liebler,et al.  Fatty Acid , 2020, Definitions.

[2]  L. Zheng,et al.  Oncolytic Viruses and Their Application to Cancer Treatment , 2019, International Archives of Clinical Pharmacology.

[3]  J. Connor,et al.  MLN8237 treatment in an orthoxenograft murine model for malignant peripheral nerve sheath tumors. , 2019, Journal of neurosurgery.

[4]  A. Stemmer-Rachamimov,et al.  Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis. , 2018, Cancer cell.

[5]  Andrew A. Rooney,et al.  Facilitating healthcare decisions by assessing the certainty in the evidence from preclinical animal studies , 2018, PloS one.

[6]  Franziska Michor,et al.  mTOR and HDAC Inhibitors Converge on the TXNIP/Thioredoxin Pathway to Cause Catastrophic Oxidative Stress and Regression of RAS-Driven Tumors. , 2017, Cancer discovery.

[7]  Robin L. Jones,et al.  SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors , 2017, Sarcoma.

[8]  Frank McCormick,et al.  RAS Proteins and Their Regulators in Human Disease , 2017, Cell.

[9]  J. Blay,et al.  Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. , 2017, The Lancet. Oncology.

[10]  J. Chernoff,et al.  Medium throughput biochemical compound screening identifies novel agents for pharmacotherapy of neurofibromatosis type 1. , 2017, Biochimie.

[11]  A. Lazar,et al.  Targeting Group I p21-Activated Kinases to Control Malignant Peripheral Nerve Sheath Tumor Growth and Metastasis , 2017, Oncogene.

[12]  G. Schwartz,et al.  Selinexor (KPT-330) Induces Tumor Suppression through Nuclear Sequestration of IκB and Downregulation of Survivin , 2017, Clinical Cancer Research.

[13]  N. Ratner,et al.  Aurora A kinase inhibition enhances oncolytic herpes virotherapy through cytotoxic synergy and innate cellular immune modulation , 2017, Oncotarget.

[14]  N. Ishiguro,et al.  Antitumor effects of 4‐methylumbelliferone, a hyaluronan synthesis inhibitor, on malignant peripheral nerve sheath tumor , 2017, International journal of cancer.

[15]  A. Look,et al.  Overexpression of PDGFRA cooperates with loss of NF1 and p53 to accelerate the molecular pathogenesis of malignant peripheral nerve sheath tumors , 2016, Oncogene.

[16]  Robin L. Jones,et al.  SARC 006 : Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors , 2017 .

[17]  Elizabeth E. Sweeney,et al.  Photothermal therapy improves the efficacy of a MEK inhibitor in neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors , 2016, Scientific Reports.

[18]  D. Lev,et al.  Verticillin A Inhibits Leiomyosarcoma and Malignant Peripheral Nerve Sheath Tumor Growth via Induction of Apoptosis , 2016, Clinical & experimental pharmacology.

[19]  G. Schwartz,et al.  Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  D. Largaespada,et al.  CK2 blockade causes MPNST cell apoptosis and promotes degradation of β-catenin , 2016, Oncotarget.

[21]  E. Legius,et al.  Cotargeting MNK and MEK kinases induces the regression of NF1-mutant cancers. , 2016, The Journal of clinical investigation.

[22]  S. Steinberg,et al.  SARC016: Phase II study of everolimus in combination with bevacizumab in sporadic and neurofibromatosis type 1 (NF1) related refractory malignant peripheral nerve sheath tumors (MPNST). , 2016 .

[23]  Dafydd G. Thomas,et al.  SARC009: Phase 2 study of dasatinib in patients with previously treated, high‐grade, advanced sarcoma , 2016, Cancer.

[24]  F. Bertucci,et al.  Management and prognosis of malignant peripheral nerve sheath tumors: The experience of the French Sarcoma Group (GSF-GETO). , 2016, European journal of cancer.

[25]  Kai Huang,et al.  Poly (ADP) ribose polymerase inhibition: A potential treatment of malignant peripheral nerve sheath tumor , 2016, Cancer biology & therapy.

[26]  N. Ratner,et al.  Fatty acid synthase is a metabolic oncogene targetable in malignant peripheral nerve sheath tumors. , 2015, Neuro-oncology.

[27]  A. Carnero,et al.  Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA , 2015, Oncotarget.

[28]  G. Schwartz,et al.  Inhibition of polo like kinase 1 in sarcomas induces apoptosis that is dependent on Mcl-1 suppression , 2015, Cell cycle.

[29]  R. Pollock,et al.  HDAC8, A Potential Therapeutic Target for the Treatment of Malignant Peripheral Nerve Sheath Tumors (MPNST) , 2015, PloS one.

[30]  D. Babovic‐Vuksanovic,et al.  Oncolytic measles virus as a novel therapy for malignant peripheral nerve sheath tumors. , 2015, Gene.

[31]  X. Puente,et al.  Comprehensive establishment and characterization of orthoxenograft mouse models of malignant peripheral nerve sheath tumors for personalized medicine , 2015, EMBO molecular medicine.

[32]  A. Kim,et al.  Current Treatment Options for Malignant Peripheral Nerve Sheath Tumors , 2015, Current Treatment Options in Oncology.

[33]  A. Lazar,et al.  Antitumor effects of pharmacological EZH2 inhibition on malignant peripheral nerve sheath tumor through the miR-30a and KPNB1 pathway , 2015, Molecular Cancer.

[34]  K. Camphausen,et al.  Radiation Therapy in Management of Sporadic and Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors , 2014, Front. Oncol..

[35]  J. F. Longo,et al.  Combinatorial Therapy With Tamoxifen and Trifluoperazine Effectively Inhibits Malignant Peripheral Nerve Sheath Tumor Growth by Targeting Complementary Signaling Cascades , 2014, Journal of neuropathology and experimental neurology.

[36]  Eric Legius,et al.  PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies , 2014, Nature.

[37]  O. Maertens,et al.  Defining key signaling nodes and therapeutic biomarkers in NF1-mutant cancers. , 2014, Cancer discovery.

[38]  A. Kuramochi,et al.  Translationally Controlled Tumor Protein Is a Novel Biological Target for Neurofibromatosis Type 1-associated Tumors* , 2014, The Journal of Biological Chemistry.

[39]  R. Martuza,et al.  Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus. , 2014, Neuro-oncology.

[40]  C. Breitbach,et al.  Going viral with cancer immunotherapy , 2014, Nature Reviews Cancer.

[41]  G. Schwartz,et al.  Sustained Inhibition of Receptor Tyrosine Kinases and Macrophage Depletion by PLX3397 and Rapamycin as a Potential New Approach for the Treatment of MPNSTs , 2014, Clinical Cancer Research.

[42]  J. Blay,et al.  Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. , 2014, The Lancet. Oncology.

[43]  S. Rabkin,et al.  Oncolytic Viruses and Their Application to Cancer Immunotherapy , 2014, Cancer Immunology Research.

[44]  G. Riggins,et al.  Preclinical evaluation of the combination of mTOR and proteasome inhibitors with radiotherapy in malignant peripheral nerve sheath tumors , 2014, Journal of Neuro-Oncology.

[45]  N. M. Powell,et al.  Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity , 2014, Oncotarget.

[46]  C. Liao,et al.  BET bromodomain inhibition triggers apoptosis of NF1-associated malignant peripheral nerve sheath tumors through Bim induction. , 2014, Cell reports.

[47]  M. Ghert,et al.  Lost in translation: animal models and clinical trials in cancer treatment. , 2014, American journal of translational research.

[48]  A. Stemmer-Rachamimov,et al.  EGFR–STAT3 signaling promotes formation of malignant peripheral nerve sheath tumors , 2014, Oncogene.

[49]  A. Kurtz,et al.  Effects of pigment epithelium derived factor (PEDF) on malignant peripheral nerve sheath tumours (MPNSTs) , 2013, Journal of Neuro-Oncology.

[50]  L. Zelek,et al.  Chemotherapy for the treatment of malignant peripheral nerve sheath tumors in neurofibromatosis 1: a 10-year institutional review , 2013, Orphanet Journal of Rare Diseases.

[51]  Jeffrey K. Mito,et al.  NF1 Deletion Generates Multiple Subtypes of Soft-Tissue Sarcoma That Respond to MEK Inhibition , 2013, Molecular Cancer Therapeutics.

[52]  I. Bièche,et al.  MicroRNAome profiling in benign and malignant neurofibromatosis type 1-associated nerve sheath tumors: evidences of PTEN pathway alterations in early NF1 tumorigenesis , 2013, BMC Genomics.

[53]  N. Rosen,et al.  ERK pathway inhibitors: how low should we go? , 2013, Cancer discovery.

[54]  C. Creighton,et al.  CXCR4/CXCL12 Mediate Autocrine Cell- Cycle Progression in NF1-Associated Malignant Peripheral Nerve Sheath Tumors , 2013, Cell.

[55]  G. Page,et al.  MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. , 2013, The Journal of clinical investigation.

[56]  J. Keats,et al.  Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition , 2013, Oncotarget.

[57]  Y. Yamashita,et al.  Imatinib mesylate inhibits cell growth of malignant peripheral nerve sheath tumors in vitro and in vivo through suppression of PDGFR-β , 2013, BMC Cancer.

[58]  Y. Iwamoto,et al.  Prognostic Significance of AKT/mTOR and MAPK Pathways and Antitumor Effect of mTOR Inhibitor in NF1-Related and Sporadic Malignant Peripheral Nerve Sheath Tumors , 2012, Clinical Cancer Research.

[59]  M. Zhang,et al.  Effect of Triptolide on Malignant Peripheral Nerve Sheath Tumours In Vitro and In Vivo , 2012, The Journal of international medical research.

[60]  B. Aronow,et al.  Ras-Driven Transcriptome Analysis Identifies Aurora Kinase A as a Potential Malignant Peripheral Nerve Sheath Tumor Therapeutic Target , 2012, Clinical Cancer Research.

[61]  J. Blay,et al.  Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial , 2012, The Lancet.

[62]  D. Cooper,et al.  Microarray‐based copy number analysis of neurofibromatosis type‐1 (NF1)‐associated malignant peripheral nerve sheath tumors reveals a role for Rho–GTPase pathway genes in NF1 tumorigenesis , 2012, Human mutation.

[63]  C. Creighton,et al.  Survivin Is a Viable Target for the Treatment of Malignant Peripheral Nerve Sheath Tumors , 2012, Clinical Cancer Research.

[64]  B. Pockaj,et al.  Malignant Peripheral Nerve Sheath Tumors (MPNST): The Mayo Clinic Experience , 2012, Annals of Surgical Oncology.

[65]  T. de Ravel,et al.  Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors , 2011, Genes, chromosomes & cancer.

[66]  Kwok-Kin Wong,et al.  Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. , 2011, Cancer cell.

[67]  Jun Liu,et al.  Activated MET Is a Molecular Prognosticator and Potential Therapeutic Target for Malignant Peripheral Nerve Sheath Tumors , 2011, Clinical Cancer Research.

[68]  L. Mariani,et al.  Non-metastatic unresected paediatric non-rhabdomyosarcoma soft tissue sarcomas: results of a pooled analysis from United States and European groups. , 2011, European journal of cancer.

[69]  J. Kappes,et al.  Tamoxifen inhibits malignant peripheral nerve sheath tumor growth in an estrogen receptor-independent manner. , 2011, Neuro-oncology.

[70]  A. Lazar,et al.  Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors. , 2011, Cancer research.

[71]  M. van Glabbeke,et al.  First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC soft tissue and bone sarcoma group study. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[72]  B. Aronow,et al.  Molecular engineering and validation of an oncolytic herpes simplex virus type 1 transcriptionally targeted to midkine‐positive tumors , 2010, The journal of gene medicine.

[73]  K. Reilly,et al.  The neurofibromatosis type 1 tumor suppressor controls cell growth by regulating signal transducer and activator of transcription-3 activity in vitro and in vivo. , 2010, Cancer research.

[74]  Paul A Meyers,et al.  Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  L. Qin,et al.  Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  Wei-Lien Wang,et al.  Clinical, Pathological, and Molecular Variables Predictive of Malignant Peripheral Nerve Sheath Tumor Outcome , 2009, Annals of surgery.

[77]  Shanta M. Messerli,et al.  CAPE (caffeic acid phenethyl ester)‐based propolis extract (Bio 30) suppresses the growth of human neurofibromatosis (NF) tumor xenografts in mice , 2009, Phytotherapy research : PTR.

[78]  B. Aronow,et al.  Molecular analysis of human cancer cells infected by an oncolytic HSV-1 reveals multiple upregulated cellular genes and a role for SOCS1 in virus replication , 2008, Cancer Gene Therapy.

[79]  H. Lane,et al.  Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors , 2008, Molecular Cancer Therapeutics.

[80]  J. Clegg,et al.  Management and Prognosis , 2008 .

[81]  Joseph Zeidner,et al.  The pediatric preclinical testing program: Description of models and early testing results , 2007, Pediatric blood & cancer.

[82]  T. Crombleholme,et al.  Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[83]  H. Fukuhara,et al.  Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[84]  H. Fukuhara,et al.  Dominant-Negative Fibroblast Growth Factor Receptor Expression Enhances Antitumoral Potency of Oncolytic Herpes Simplex Virus in Neural Tumors , 2006, Clinical Cancer Research.

[85]  C. Mussi,et al.  Malignant peripheral nerve sheath tumors , 2006, Cancer.

[86]  G. T. Budd,et al.  Phase II study of erlotinib in metastatic or unresectable malignant peripheral nerve sheath tumors (MPNST). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  T. Nheu,et al.  Sichuan pepper extracts block the PAK1/Cyclin D1 pathway and the growth of NF1-deficient cancer xenograft in mice , 2006, Cancer biology & therapy.

[88]  O. Fain.  [Neurofibromatosis type I]. , 2006, La Revue du praticien.

[89]  A. Ferrari,et al.  Pediatric malignant peripheral nerve sheath tumor: the Italian and German soft tissue sarcoma cooperative group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  G. Mashour,et al.  Differential modulation of malignant peripheral nerve sheath tumor growth by omega-3 and omega-6 fatty acids , 2005, Oncogene.

[91]  A. Kurtz,et al.  Signal therapy of NF1-deficient tumor xenograft in mice by the anti-PAK1 drug FK228 , 2005, Cancer biology & therapy.

[92]  S. Velasco-Miguel,et al.  Epidermal growth factor receptor signaling pathways are associated with tumorigenesis in the Nf1:p53 mouse tumor model. , 2002, Cancer research.

[93]  Mohsen Farahani,et al.  Photothermal therapy , 2002, Other Conferences.

[94]  L. Kluwe,et al.  Allelic loss of the NF1 gene in NF1-associated plexiform neurofibromas. , 1999, Cancer genetics and cytogenetics.

[95]  E. Sausville,et al.  US-NCI Testing Procedures , 1999 .

[96]  B. Scheithauer,et al.  Malignant peripheral nerve sheath tumor: analysis of treatment outcome. , 1998, International journal of radiation oncology, biology, physics.

[97]  H. Niitani,et al.  [Phase II study]. , 1995, Gan to kagaku ryoho. Cancer & chemotherapy.

[98]  P. Marynen,et al.  TP53 mutations are frequent in malignant NFI tumors , 1994, Genes, chromosomes & cancer.

[99]  F. Collins,et al.  Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients , 1992, Nature.

[100]  B. Scheithauer,et al.  Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases , 1986, Cancer.